查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1625245

2030 年腎上腺素自動注射器市場預測：按產品、劑量、年齡層、品牌、應用、最終用戶和地區進行的全球分析

Epinephrine Auto-Injectors Market Forecasts to 2030 - Global Analysis By Product (Single-dose Auto-Injectors and Multi-dose Auto-Injectors), Dosage, Age Group, Brand, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球腎上腺素自動注射器市場規模為 23.3 億美元，預計預測期內複合年成長率為 6.3%，到 2030 年將達到 33.7 億美元。

腎上腺素自動注射器是醫療設備，腎上腺素是一種用於治療嚴重過敏反應（過敏反應）的救命藥物。這些緊湊的攜帶式設備含有預先測量的腎上腺素，並具有彈簧加載機構，可快速注射到大腿肌肉中。它透過收縮血管和放鬆氣道肌肉來快速緩解症狀，逆轉腫脹、低血壓和呼吸困難等症狀。它通常被患有嚴重過敏的人使用，對於在危及生命的過敏緊急情況下即時做出反應至關重要。

根據世界衛生組織(WHO)的報告，到2021年，全球每年注射次數將超過160億次，注射次數的增加正在推動自動注射器市場的發展。

過敏反應增加

嚴重過敏反應的病例數正在增加，因此及時採取替代治療的需求變得越來越重要。腎上腺素自動注射器提供了一種在緊急情況下施用救生藥物的快速便捷的方法。人們對過敏反應及其風險的認知不斷提高，導致對這些設備的需求增加。自動注射器技術的進步提供了一個易於使用的設計，進一步推動了市場的發展。隨著高風險族群的增加，腎上腺素自動注射器正成為管理過敏反應的重要工具，確保市場的持續成長。

產品召回和缺陷

產品召回和缺陷會帶來嚴重的健康風險，例如自動注射器無法在緊急情況下準確注射劑量，導致使用者不願意依賴自動注射器。召回會擾亂供應鏈，導致短缺，並使患者無法獲得關鍵的醫療設備。此外，召回往往會導致監管審查加強，從而減緩新產品核准和市場擴張。召回和相關訴訟的財務負擔也會影響製造商，限制他們投資創新的能力。

擴大適應症

隨著食物過敏和昆蟲叮咬等需要即時使用腎上腺素治療的新疾病的出現，對自動注射器的需求不斷增加。此外，醫療機構越來越認知到攜帶自動注射器以供緊急使用的重要性，進一步增加了其採用率。隨著人們的廣泛使用，市場規模不斷擴大。配方和設備設計的進步也有助於提高患者的依從性和易用性。最終，擴大適應症將提高認知度和進入率，推動市場滲透和銷售成長。

法律和道德問題

自動注射器的高成本通常是由於專利保護，這引發了有關可及性的道德問題，特別是對於低收入患者而言。圍繞定價和壟斷行為的監管障礙和訴訟為製造商創造了充滿挑戰的法律環境。學名藥的缺乏、可負擔性和市場競爭有限也引起了倫理問題。與設備故障和濫用相關的責任問題進一步抑制了創新和投資。總的來說，這些因素阻礙了救生自動注射器的市場成長和廣泛採用。

COVID-19 的影響

COVID-19 大流行對腎上腺素自動注射器市場產生了重大影響。供應鏈中斷、醫療機構患者就診人數減少以及選擇性治療的延遲最初阻礙了市場成長。然而，人們對呼吸健康和自我護理的興趣日益濃厚，導致對家庭治療解決方案的需求增加，從而使市場受益。遠端醫療和線上藥局已成為停工期間的主要分銷管道。製造商的應對措施是增加產量並確保准入。隨著醫療保健的改善和供應鏈在疫情後的正常化，市場表現出韌性，逐漸復甦。

單劑量自動注射器細分市場預計將成為預測期內最大的細分市場

透過為面臨嚴重過敏反應的人們提供便利和易用性，單劑量自動注射器市場預計將出現良好的成長。這些設備允許快速自我管理，並能夠在緊急情況下及時管理腎上腺素。它們也被設計為便攜的，適合在旅途中使用，從而提高了採用率。此外，監管部門的核准和設計創新正在提高單劑量自動注射器的可用性和有效性。因此，該細分市場繼續為整體市場成長做出重大貢獻。

預計醫院業在預測期內複合年成長率最高。

由於可以即時獲得針對過敏性緊急情況的救生治療，預計醫院部門在預測期內將出現最高的複合年成長率。醫院通常是嚴重過敏反應患者的主要治療地點，及時給予腎上腺素至關重要。隨著全球過敏反應的增加，醫院正在儲備更多的自動注射器以滿足緊急需求。此外，醫療保健專業人員對腎上腺素自動注射器使用的認知和培訓正在推動醫院的採用。

比最大的地區

由於人們對過敏反應及其管理的認知不斷提高，食物過敏和其他嚴重過敏反應的盛行率不斷增加，預計亞太地區將在預測期內佔據最大的市場佔有率。由於政府努力改善醫療保健和促進過敏管理，中國、印度和日本等國家的需求不斷成長。自動注射器設計的技術進步，包括緊湊且易於使用的設備，也正在推動採用。此外，製藥公司增加的投資和當地製造的合作夥伴關係正在提高整個全部區域的可用性和可負擔性。

複合年成長率最高的地區：

由於過敏反應和過敏的盛行率不斷增加，預計北美在預測期內將出現最高的複合年成長率。人們對過敏反應緊急治療的認知不斷提高以及對及時醫療干預的需求正在推動需求。美國因其高滲透率、醫療保健基礎設施以及 EpiPen 和 Auvi-Q 等各種品牌的可用性而佔據市場主導地位。隨著保險覆蓋範圍的擴大，監理支持進一步提振市場。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球腎上腺素自動注射器市場：按產品

  • 單劑量自動注射器
  • 多劑量自動注射器

第6章全球腎上腺素自動注射器市場：按劑量

  • 0.15mg
  • 0.3mg
  • 其他劑量

第7章全球腎上腺素自動注射器市場：依年齡層

  • 0-4歲
  • 5-14歲
  • 15-24歲
  • 25-49歲
  • 50-64歲
  • 65歲以上
  • 其他年齡段

第8章全球腎上腺素自動注射器市場：按品牌

  • EpiPen（邁蘭/比阿特麗斯）
  • Auvi-Q（卡雷奧）
  • Adrenaclick（Enfaster 製藥公司）
  • 非專利版本
  • 其他品牌

第9章全球腎上腺素自動注射器市場：依應用分類

  • 過敏反應
  • 食物過敏
  • 藥物過敏
  • 其他用途

第10章全球腎上腺素自動注射器市場：依最終用戶分類

  • 醫院
  • 診所
  • 家庭護理設置
  • 其他最終用戶

第11章全球腎上腺素自動注射器市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章 公司概況

  • Viatris Inc.
  • Amneal Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Kaleo, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Adamis Pharmaceuticals Corporation
  • Novartis International AG
  • Bausch Health Companies Inc.
  • ALK-Abello A/S
  • Hikma Pharmaceuticals PLC
  • Antares Pharma, Inc.
  • Meridian Medical Technologies, Inc.
  • Becton, Dickinson and Company
  • Ypsomed Holding AG
Product Code: SMRC28200

According to Stratistics MRC, the Global Epinephrine Auto-Injectors Market is accounted for $2.33 billion in 2024 and is expected to reach $3.37 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Epinephrine auto-injectors are medical devices designed for emergency self-administration of epinephrine, a life-saving medication used to treat severe allergic reactions (anaphylaxis). These compact, portable devices contain a pre-measured dose of epinephrine and feature a spring-loaded mechanism for rapid injection into the thigh muscle. They provide quick relief by constricting blood vessels, relaxing airway muscles, and reversing symptoms like swelling, low blood pressure, and breathing difficulties. Commonly used by individuals with severe allergies, they are essential for immediate response during life-threatening allergic emergencies.

According to World Health Organization reports, over 16 billion injections were administered annually worldwide in 2021, stimulated by the increasing number of injections administered boosting the auto injector market.

Market Dynamics:

Driver:

Rising prevalence of anaphylaxis

The number of cases of severe allergic responses rises; the necessity for quick treatment alternatives becomes increasingly important. Epinephrine auto-injectors provide a fast and convenient way to administer life-saving medication in emergencies. Growing awareness about anaphylaxis and its risks has led to a heightened demand for these devices. The market is further fuelled by advancements in auto-injector technology, offering user-friendly designs. With an expanding at-risk population, epinephrine auto-injectors are becoming an essential tool for managing anaphylaxis, ensuring a sustained market growth.

Restraint:

Product recalls and malfunctions

Product recalls and malfunctions like failed delivery of auto-injectors to accurate doses during emergencies, it poses severe health risks, deterring users from relying on them. Recalls disrupt the supply chain and create shortages, leaving patients without access to critical medical devices. Additionally, recalls often lead to increased regulatory scrutiny, delaying new product approvals and market expansions. The financial burden of recalls and associated lawsuits also impacts manufacturers, limiting their ability to invest in innovation.

Opportunity:

Expansion of indications

The new medical conditions, such as food allergies and insect stings, are identified as requiring immediate epinephrine treatment, the demand for auto-injectors rises. Additionally, healthcare organizations are increasingly recognizing the importance of carrying auto-injectors for emergency use, further increasing their adoption. This broader usage across various demographics enhances market reach. Advancements in formulation and device design also contribute to greater patient compliance and ease of use. Ultimately, the expanded indications improve awareness and access, driving higher market penetration and sales.

Threat:

Legal and ethical concerns

High prices of auto-injectors, often attributed to patent protections, raise ethical questions about accessibility, especially for low-income patients. Regulatory hurdles and lawsuits over pricing and monopolistic practices create a challenging legal environment for manufacturers. Ethical concerns also arise from a lack of generic alternatives, limiting affordability and market competition. Liability issues related to device malfunctions or incorrect usage further deter innovation and investment. These factors collectively hinder the market's growth and broader adoption of life-saving auto-injectors.

Covid-19 Impact

The COVID-19 pandemic significantly impacted the epinephrine auto-injectors market. Disruptions in supply chains, reduced patient visits to healthcare facilities, and delayed elective treatments initially hindered market growth. However, the heightened focus on respiratory health and self-care led to increased demand for at-home treatment solutions, benefiting the market. Telemedicine and online pharmacies emerged as key distribution channels during lockdowns. Manufacturers adapted by ramping up production and ensuring accessibility. The market demonstrated resilience, with gradual recovery aligning with improved healthcare access and the normalization of supply chains post-pandemic.

The single-dose auto-injectors segment is expected to be the largest during the forecast period

The single-dose auto-injectors segment is estimated to have a lucrative growth, by offering convenience and ease of use for individuals facing severe allergic reactions. These devices provide quick, self-administered doses, ensuring timely epinephrine delivery in emergencies. They are designed for portability, making them suitable for on-the-go use, which increases their adoption rates. Furthermore, regulatory approvals and innovations in design have enhanced the accessibility and effectiveness of single-dose auto-injectors. As a result, this segment continues to contribute significantly to the growth of the overall market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, due to immediate access to life-saving treatment for anaphylactic emergencies. Hospitals often serve as the primary setting for patients experiencing severe allergic reactions, where rapid administration of epinephrine is critical. With increasing allergic reactions globally, hospitals are stocking more auto-injectors to meet emergency needs. Additionally, healthcare professionals' awareness and training in using epinephrine auto-injectors drive their adoption in hospitals.

Region with largest share:

Asia Pacific is expected to hold the largest market share during the forecast period due to rising awareness of anaphylaxis and its management, coupled with increasing prevalence of food allergies and other severe allergic reactions. Countries like China, India, and Japan are seeing growing demand due to improved healthcare access and government initiatives promoting allergy management. Technological advancements in auto-injector design, such as compact and user-friendly devices, are also boosting adoption. Additionally, rising investments by pharmaceutical companies and collaborations for local manufacturing are enhancing availability and affordability across the region.

Region with highest CAGR:

North America is expected to have the highest CAGR over the forecast period, owing to increasing prevalence of anaphylactic reactions and allergies. Rising awareness about emergency treatment for allergic reactions and the need for quick medical intervention are boosting demand. The U.S. dominates the market due to high adoption rates, healthcare infrastructure, and the availability of various brands like EpiPen and Auvi-Q. Regulatory support, along with expanding insurance coverage, is further propelling the market.

Key players in the market

Some of the key players profiled in the Epinephrine Auto-Injectors Market include Viatris Inc., Amneal Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Kaleo, Inc., Pfizer, Inc., Sanofi S.A., Adamis Pharmaceuticals Corporation, Novartis International AG, Bausch Health Companies Inc., ALK-Abello A/S, Hikma Pharmaceuticals PLC, Antares Pharma, Inc., Meridian Medical Technologies, Inc., Becton, Dickinson and Company and Ypsomed Holding AG.

Key Developments:

In October 2024, Viatris entered into an exclusive licensing agreement to acquire rights to sotagliflozin in all markets outside the U.S. and Europe. The partnership aims to enhance the commercial reach of sotagliflozin, which is relevant for patients with diabetes and heart failure.

In February 2024, Viatris announced a significant global research and development collaboration with Idorsia Ltd. The collaboration aims to leverage Viatris' infrastructure alongside Idorsia's drug development capabilities.

Products Covered:

  • Single-dose Auto-Injectors
  • Multi-dose Auto-Injectors

Dosages Covered:

  • 0.15 mg
  • 0.3 mg
  • Other Dosages

Age Groups Covered:

  • 0-4 Years
  • 5-14 Years
  • 15-24 Years
  • 25-49 Years
  • 50-64 Years
  • Above 65 Years
  • Other Age Groups

Brands Covered:

  • EpiPen (Mylan/Viatris)
  • Auvi-Q (Kaleo)
  • Adrenaclick (Amphastar Pharmaceuticals)
  • Generic Versions
  • Other Brands

Applications Covered:

  • Anaphylaxis
  • Food Allergies
  • Drug Allergies
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epinephrine Auto-Injectors Market, By Product

  • 5.1 Introduction
  • 5.2 Single-dose Auto-Injectors
  • 5.3 Multi-dose Auto-Injectors

6 Global Epinephrine Auto-Injectors Market, By Dosage

  • 6.1 Introduction
  • 6.2 0.15 mg
  • 6.3 0.3 mg
  • 6.4 Other Dosages

7 Global Epinephrine Auto-Injectors Market, By Age Group

  • 7.1 Introduction
  • 7.2 0-4 Years
  • 7.3 5-14 Years
  • 7.4 15-24 Years
  • 7.5 25-49 Years
  • 7.6 50-64 Years
  • 7.7 Above 65 Years
  • 7.8 Other Age Groups

8 Global Epinephrine Auto-Injectors Market, By Brand

  • 8.1 Introduction
  • 8.2 EpiPen (Mylan/Viatris)
  • 8.3 Auvi-Q (Kaleo)
  • 8.4 Adrenaclick (Amphastar Pharmaceuticals)
  • 8.5 Generic Versions
  • 8.6 Other Brands

9 Global Epinephrine Auto-Injectors Market, By Application

  • 9.1 Introduction
  • 9.2 Anaphylaxis
  • 9.3 Food Allergies
  • 9.4 Drug Allergies
  • 9.5 Other Applications

10 Global Epinephrine Auto-Injectors Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics
  • 10.4 Homecare Settings
  • 10.5 Other End Users

11 Global Epinephrine Auto-Injectors Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Viatris Inc.
  • 13.2 Amneal Pharmaceuticals, Inc.
  • 13.3 Teva Pharmaceutical Industries Ltd.
  • 13.4 Kaleo, Inc.
  • 13.5 Pfizer, Inc.
  • 13.6 Sanofi S.A.
  • 13.7 Adamis Pharmaceuticals Corporation
  • 13.8 Novartis International AG
  • 13.9 Bausch Health Companies Inc.
  • 13.10 ALK-Abello A/S
  • 13.11 Hikma Pharmaceuticals PLC
  • 13.12 Antares Pharma, Inc.
  • 13.13 Meridian Medical Technologies, Inc.
  • 13.14 Becton, Dickinson and Company
  • 13.15 Ypsomed Holding AG

List of Tables

  • Table 1 Global Epinephrine Auto-Injectors Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Epinephrine Auto-Injectors Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Epinephrine Auto-Injectors Market Outlook, By Single-dose Auto-Injectors (2022-2030) ($MN)
  • Table 4 Global Epinephrine Auto-Injectors Market Outlook, By Multi-dose Auto-Injectors (2022-2030) ($MN)
  • Table 5 Global Epinephrine Auto-Injectors Market Outlook, By Dosage (2022-2030) ($MN)
  • Table 6 Global Epinephrine Auto-Injectors Market Outlook, By 0.15 mg (2022-2030) ($MN)
  • Table 7 Global Epinephrine Auto-Injectors Market Outlook, By 0.3 mg (2022-2030) ($MN)
  • Table 8 Global Epinephrine Auto-Injectors Market Outlook, By Other Dosages (2022-2030) ($MN)
  • Table 9 Global Epinephrine Auto-Injectors Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 10 Global Epinephrine Auto-Injectors Market Outlook, By 0-4 Years (2022-2030) ($MN)
  • Table 11 Global Epinephrine Auto-Injectors Market Outlook, By 5-14 Years (2022-2030) ($MN)
  • Table 12 Global Epinephrine Auto-Injectors Market Outlook, By 15-24 Years (2022-2030) ($MN)
  • Table 13 Global Epinephrine Auto-Injectors Market Outlook, By 25-49 Years (2022-2030) ($MN)
  • Table 14 Global Epinephrine Auto-Injectors Market Outlook, By 50-64 Years (2022-2030) ($MN)
  • Table 15 Global Epinephrine Auto-Injectors Market Outlook, By Above 65 Years (2022-2030) ($MN)
  • Table 16 Global Epinephrine Auto-Injectors Market Outlook, By Other Age Groups (2022-2030) ($MN)
  • Table 17 Global Epinephrine Auto-Injectors Market Outlook, By Brand (2022-2030) ($MN)
  • Table 18 Global Epinephrine Auto-Injectors Market Outlook, By EpiPen (Mylan/Viatris) (2022-2030) ($MN)
  • Table 19 Global Epinephrine Auto-Injectors Market Outlook, By Auvi-Q (Kaleo) (2022-2030) ($MN)
  • Table 20 Global Epinephrine Auto-Injectors Market Outlook, By Adrenaclick (Amphastar Pharmaceuticals) (2022-2030) ($MN)
  • Table 21 Global Epinephrine Auto-Injectors Market Outlook, By Generic Versions (2022-2030) ($MN)
  • Table 22 Global Epinephrine Auto-Injectors Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 23 Global Epinephrine Auto-Injectors Market Outlook, By Application (2022-2030) ($MN)
  • Table 24 Global Epinephrine Auto-Injectors Market Outlook, By Anaphylaxis (2022-2030) ($MN)
  • Table 25 Global Epinephrine Auto-Injectors Market Outlook, By Food Allergies (2022-2030) ($MN)
  • Table 26 Global Epinephrine Auto-Injectors Market Outlook, By Drug Allergies (2022-2030) ($MN)
  • Table 27 Global Epinephrine Auto-Injectors Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 28 Global Epinephrine Auto-Injectors Market Outlook, By End User (2022-2030) ($MN)
  • Table 29 Global Epinephrine Auto-Injectors Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 30 Global Epinephrine Auto-Injectors Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 31 Global Epinephrine Auto-Injectors Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 32 Global Epinephrine Auto-Injectors Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.